NCT04065932View on ClinicalTrials.gov

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

December 8, 2019

Study Completion Date

December 10, 2019

Conditions
Lupus
Interventions
DRUG

BMS-986165-01

Participants will receive BMS- 986165 -01 in prototype formulation

DRUG

BMS-986165 Tablet

Participants will receive BMS-986165 in tablet form.

DRUG

Famotidine

Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY